AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15599193 — intervention group
Group type: EXPERIMENTAL
Intervention: Hearing aids + Audiological Rehabilitation (HA + AR)
Number of subjects: 106
Study 15599193 — intervention group
Group type: COMPARATOR
Intervention: Hearing aids alone (Control)
Number of subjects: 106
Study 11157562 — intervention group
Group type: EXPERIMENTAL
Intervention: High-density surface EMG (sEMG) technique
Number of subjects: 0
Study 10897096 — intervention group
Group type: EXPERIMENTAL
Intervention: Reference formulation of racemic chlorpheniramine (8 mg)
Number of subjects: 12
Study 10897096 — intervention group
Group type: COMPARATOR
Intervention: Vietnamese-tested formulation of racemic chlorpheniramine (8 mg)
Number of subjects: 12
Study 1813860 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 g vitamin C daily
Number of subjects: 105
Study 1813860 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 105
Study 6095659 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine (150 mg at bedtime)
Number of subjects: 402
Study 6095659 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 402
Study 6095659 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine (400 mg at bedtime)
Number of subjects: 402
Study 31886617 — intervention group
Group type: EXPERIMENTAL
Intervention: Improved enzyme variant (L8F/A33I/M45Y/F50A)
Number of subjects: 0
Study 31886617 — intervention group
Group type: COMPARATOR
Intervention: 4-OT variant (L8F/M45Y/F50A)
Number of subjects: 0
Study 29059415 — intervention group
Group type: EXPERIMENTAL
Intervention: Pictorial warnings
Number of subjects: 2149
Study 29059415 — intervention group
Group type: COMPARATOR
Intervention: Text-only warnings
Number of subjects: 2149
Study 26696290 — intervention group
Group type: EXPERIMENTAL
Intervention: 16-week intervention targeting home food and activity environments
Number of subjects: 349
Study 26696290 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 349
Study 24053310 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-incision mini-sling (SIMS; Ajust(®))
Number of subjects: 137
Study 24053310 — intervention group
Group type: COMPARATOR
Intervention: Standard mid-urethral sling (SMUS; TVT-O)
Number of subjects: 137
Study 21271232 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine infusion (1 µg/kg BW/h for 10 min, then 0.2-0.4 µg/kg BW/h)
Number of subjects: 20
Study 21271232 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine infusion
Number of subjects: 20
Study 18941918 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive instruction in physical examination (n = 46)
Number of subjects: 121
Study 18941918 — intervention group
Group type: COMPARATOR
Intervention: Usual instruction (control group, n = 75)
Number of subjects: 121
Study 16979847 — intervention group
Group type: EXPERIMENTAL
Intervention: Disulfiram 62.5 mg/day with cocaine 0.25 mg/kg
Number of subjects: 12
Study 16979847 — intervention group
Group type: EXPERIMENTAL
Intervention: Disulfiram 250 mg/day with cocaine 0.25 mg/kg
Number of subjects: 12
Study 16979847 — intervention group
Group type: EXPERIMENTAL
Intervention: Disulfiram 62.5 mg/day with cocaine 0.5 mg/kg
Number of subjects: 12
Study 16979847 — intervention group
Group type: EXPERIMENTAL
Intervention: Disulfiram 250 mg/day with cocaine 0.5 mg/kg
Number of subjects: 12
Study 16979847 — intervention group
Group type: COMPARATOR
Intervention: Cocaine 0.25 mg/kg
Number of subjects: 12
Study 15482040 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual-based cognitive-behavioral treatment for anxiety
Number of subjects: 59
Study 15482040 — intervention group
Group type: EXPERIMENTAL
Intervention: Child involvement at midtreatment
Number of subjects: 59
Study 15482040 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased involvement during therapy (positive involvement shifts)
Number of subjects: 59
Study 11497192 — intervention group
Group type: EXPERIMENTAL
Intervention: Isolated systolic hypertension
Number of subjects: 951
Study 11497192 — intervention group
Group type: COMPARATOR
Intervention: Combined hypertension
Number of subjects: 951
Study 10342793 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.25 mg/day bendrofluazide
Number of subjects: 12
Study 10342793 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 8115668 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 18
Study 8115668 — intervention group
Group type: EXPERIMENTAL
Intervention: Trazodone
Number of subjects: 18
Study 2812168 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily machine haemofiltration (MHF)
Number of subjects: 7
Study 2812168 — intervention group
Group type: COMPARATOR
Intervention: Continuous arteriovenous haemofiltration (CAVHF)
Number of subjects: 7
Study 1251146 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained-release KC1 preparation
Number of subjects: 10
Study 1251146 — intervention group
Group type: COMPARATOR
Intervention: Non-sustained-release KC1 coated tablet
Number of subjects: 10
Study 30739130 — intervention group
Group type: EXPERIMENTAL
Intervention: Toreforant 30 mg/day (weeks 0-52)
Number of subjects: 21
Study 30739130 — intervention group
Group type: COMPARATOR
Intervention: Placebo (weeks 0-12) followed by toreforant 30 mg/day (weeks 12-52)
Number of subjects: 21
Study 28968888 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 different ART regimens
Number of subjects: 26
Study 26184298 — intervention group
Group type: EXPERIMENTAL
Intervention: Green Tea Extract (GTE)
Number of subjects: 14
Study 26184298 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 24359521 — intervention group
Group type: EXPERIMENTAL
Intervention: Baoji Tablets 0.9 g and dummy Baoji Pills 3.7 g
Number of subjects: 288
Study 24359521 — intervention group
Group type: EXPERIMENTAL
Intervention: Dummy Baoji Tablets 0.9 g and Baoji Pills 3.7 g
Number of subjects: 288
Study 24359521 — intervention group
Group type: COMPARATOR
Intervention: Dummy Baoji Tablets 0.9 g and dummy Baoji Pills 3.7 g
Number of subjects: 288
Study 21170684 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet supplemented with CoQ (Med+CoQ diet)
Number of subjects: 20
Study 21170684 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet (Med diet)
Number of subjects: 20
Study 21170684 — intervention group
Group type: COMPARATOR
Intervention: Saturated fatty acid‐rich diet (SFA diet)
Number of subjects: 20
Study 19095421 — intervention group
Group type: EXPERIMENTAL
Intervention: EQ-5D utility score
Number of subjects: 49
Study 19095421 — intervention group
Group type: EXPERIMENTAL
Intervention: BPDSI-IV
Number of subjects: 49
Study 19095421 — intervention group
Group type: EXPERIMENTAL
Intervention: EQ-VAS
Number of subjects: 49
Study 16878346 — intervention group
Group type: EXPERIMENTAL
Intervention: Levetiracetam 1000 mg immediate release (IR) formulation
Number of subjects: 0
Study 12843690 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril
Number of subjects: 300
Study 12843690 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 300
Study 12843690 — intervention group
Group type: EXPERIMENTAL
Intervention: C‐reactive protein and von Willebrand factor levels
Number of subjects: 300
Study 10885587 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen 7 mg/kg in suspension
Number of subjects: 103
Study 10885587 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen 200 or 400mg as effervescent granules
Number of subjects: 103
Study 9058443 — intervention group
Group type: EXPERIMENTAL
Intervention: Inulin (30-35 g/d) for 1 week
Number of subjects: 0
Study 8125424 — intervention group
Group type: EXPERIMENTAL
Intervention: Digoxin (0.25 mg/day)
Number of subjects: 222
Study 8125424 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (50 mg/day)
Number of subjects: 222
Study 8125424 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 222
Study 3586003 — intervention group
Group type: EXPERIMENTAL
Intervention: Short form of the Jenkins Activity Survey (21 scored items)
Number of subjects: 1248
Study 3586003 — intervention group
Group type: COMPARATOR
Intervention: Long form of the Jenkins Activity Survey (44 items)
Number of subjects: 1248
Study 29536216 — intervention group
Group type: EXPERIMENTAL
Intervention: 7 mg transdermal nicotine
Number of subjects: 8
Study 29536216 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 28288613 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-gravity treadmill (alter G®) treatment, 20 min sessions, 2-3 times per week for 6 weeks
Number of subjects: 120
Study 28288613 — intervention group
Group type: COMPARATOR
Intervention: Standard physiotherapy
Number of subjects: 120
Study 25402332 — intervention group
Group type: EXPERIMENTAL
Intervention: Reparixin
Number of subjects: 32
Study 25402332 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 23530100 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-gene recurrence score (RS) assessment
Number of subjects: 162
Study 23530100 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-gene recurrence score (RS) in T3 MMR-intact (MMR-I) patients
Number of subjects: 162
Study 23530100 — intervention group
Group type: EXPERIMENTAL
Intervention: Mismatch repair (MMR) gene deficiency
Number of subjects: 162
Study 21953799 — intervention group
Group type: EXPERIMENTAL
Intervention: Telecare program
Number of subjects: 291
Study 21953799 — intervention group
Group type: COMPARATOR
Intervention: Self-monitoring blood glucose
Number of subjects: 291
Study 18555997 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadrivalent HPV 6/11/16/18 vaccine
Number of subjects: 814
Study 16869257 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary artery bypass grafting
Number of subjects: 0
Study 12556649 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine 5 mg once daily
Number of subjects: 440
Study 12556649 — intervention group
Group type: COMPARATOR
Intervention: Losartan 50 mg once daily
Number of subjects: 440
Study 12556649 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine (after dosage adjustment)
Number of subjects: 440
Study 12556649 — intervention group
Group type: COMPARATOR
Intervention: Losartan/HCTZ (after dosage adjustment)
Number of subjects: 440
Study 12556649 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 440
Study 12556649 — intervention group
Group type: COMPARATOR
Intervention: Losartan
Number of subjects: 440
Study 12556649 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine (in African Americans)
Number of subjects: 440
Study 12556649 — intervention group
Group type: COMPARATOR
Intervention: Losartan (in African Americans)
Number of subjects: 440
Study 12556649 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine (in mostly Hispanic patients)
Number of subjects: 440
Study 12556649 — intervention group
Group type: COMPARATOR
Intervention: Losartan (in mostly Hispanic patients)
Number of subjects: 440
Study 10865310 — intervention group
Group type: EXPERIMENTAL
Intervention: Optisol
Number of subjects: 24
Study 10865310 — intervention group
Group type: COMPARATOR
Intervention: Organ culture
Number of subjects: 24
Study 9305484 — intervention group
Group type: COMPARATOR
Intervention: Standard oral rehydration solution (20 g/L glucose, 94 mmol/L sodium, 292 mOsm/kg osmolality)
Number of subjects: 6
Study 9305484 — intervention group
Group type: EXPERIMENTAL
Intervention: Polymeric glucose isotonic solution enriched with glutamine (18 g/L Glucidex 12, 14.6 g/L glutamine, 94 mmol/L sodium, 282 mOsm/kg osmolality)
Number of subjects: 6
Study 8409300 — intervention group
Group type: EXPERIMENTAL
Intervention: cisapride 20 mg b.i.d.
Number of subjects: 60
Study 8409300 — intervention group
Group type: COMPARATOR
Intervention: ranitidine 150 mg b.i.d.
Number of subjects: 60
Study 8409300 — intervention group
Group type: EXPERIMENTAL
Intervention: cisapride 20 mg b.i.d. + ranitidine 150 mg b.i.d.
Number of subjects: 60
Study 3891488 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril 25 mg
Number of subjects: 8
Study 3891488 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril 50 mg
Number of subjects: 8
Study 3891488 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 3891488 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril long-term treatment (75 or 150 mg daily)
Number of subjects: 8
Study 3891488 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (after 6.5 months)
Number of subjects: 8
Study 30019604 — intervention group
Group type: EXPERIMENTAL
Intervention: Wives' reports of IPV victimization
Number of subjects: 717
Study 30019604 — intervention group
Group type: EXPERIMENTAL
Intervention: Husbands' reports of IPV perpetration
Number of subjects: 717
Study 30019604 — intervention group
Group type: EXPERIMENTAL
Intervention: Factors associated with discordant reporting
Number of subjects: 717
Study 31069579 — intervention group
Group type: EXPERIMENTAL
Intervention: HIPEC treatment
Number of subjects: 282
Study 31069579 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative systemic chemotherapy
Number of subjects: 282
Study 31069579 — intervention group
Group type: COMPARATOR
Intervention: Control group (no HIPEC)
Number of subjects: 282
Study 30172703 — intervention group
Group type: EXPERIMENTAL
Intervention: Purified CD34+ cells (PCCs)
Number of subjects: 50
Study 30172703 — intervention group
Group type: COMPARATOR
Intervention: Peripheral blood mononuclear cells (PBMNCs)
Number of subjects: 50
Study 26947102 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention
Number of subjects: 199
Study 26947102 — intervention group
Group type: COMPARATOR
Intervention: Collaborative educational program
Number of subjects: 199
Study 25182247 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban (20 mg once daily, 15 mg if creatinine clearance was between 30 and 49 mL/min)
Number of subjects: 1504
Study 25182247 — intervention group
Group type: COMPARATOR
Intervention: Vitamin K antagonists (VKAs)
Number of subjects: 1504
Study 25182247 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 1504
Study 22939198 — intervention group
Group type: EXPERIMENTAL
Intervention: Wake-up strokes (WUS)
Number of subjects: 17398
Study 22939198 — intervention group
Group type: COMPARATOR
Intervention: Stroke while awake (SWA)
Number of subjects: 17398
Study 20368065 — intervention group
Group type: EXPERIMENTAL
Intervention: AcrySof IQ ReSTOR SN6AD3 IOL (Group test)
Number of subjects: 70
Study 20368065 — intervention group
Group type: COMPARATOR
Intervention: AcrySof ReSTOR SN60D3 IOL (Group control)
Number of subjects: 70
Study 18950009 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultracision-harmonic scalpel
Number of subjects: 31
Study 18950009 — intervention group
Group type: COMPARATOR
Intervention: Routine operation
Number of subjects: 31
Study 16215542 — intervention group
Group type: EXPERIMENTAL
Intervention: Diode laser trabeculoplasty (DLT)
Number of subjects: 35
Study 16215542 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequency doubled Nd : YAG laser trabeculoplasty (YLT)
Number of subjects: 35
Study 12668512 — intervention group
Group type: EXPERIMENTAL
Intervention: CRT on
Number of subjects: 323
Study 12668512 — intervention group
Group type: COMPARATOR
Intervention: CRT off
Number of subjects: 323
Study 10647267 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate 10 mg daily
Number of subjects: 20
Study 10647267 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 8706533 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete object event (removal of the screen revealing a single, connected rectangle)
Number of subjects: 0
Study 8706533 — intervention group
Group type: EXPERIMENTAL
Intervention: Broken object event (removal of the screen revealing an interrupted rectangle with a gap)
Number of subjects: 0
Study 8706533 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectangle event (removal of the screen revealing a rectangle)
Number of subjects: 0
Study 8706533 — intervention group
Group type: EXPERIMENTAL
Intervention: Cross-shape event (removal of the screen revealing a cross-shaped object)
Number of subjects: 0
Study 8706533 — intervention group
Group type: COMPARATOR
Intervention: Baseline control conditions
Number of subjects: 0
Study 1659437 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (80 mg twice daily) plus sumatriptan (300 mg orally)
Number of subjects: 10
Study 1659437 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus sumatriptan (300 mg orally)
Number of subjects: 10
Study 6108728 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanyl 6.4 micrograms/kg
Number of subjects: 5
Study 6108728 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanyl 1.6 and 3.2 micrograms/kg
Number of subjects: 5
Study 6108728 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanyl
Number of subjects: 5
Study 6108728 — intervention group
Group type: COMPARATOR
Intervention: Saline control
Number of subjects: 5
Study 31593582 — intervention group
Group type: EXPERIMENTAL
Intervention: Ovarian biopsying followed by autotransplantation of fragmented cortical tissue
Number of subjects: 20
Study 31593582 — intervention group
Group type: COMPARATOR
Intervention: Control ovary (non-biopsied)
Number of subjects: 20
Study 29326577 — intervention group
Group type: EXPERIMENTAL
Intervention: Active tDCS + Active PES
Number of subjects: 128
Study 29326577 — intervention group
Group type: COMPARATOR
Intervention: Active tDCS + Sham PES
Number of subjects: 128
Study 29326577 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS + Active PES
Number of subjects: 128
Study 29326577 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS + Sham PES
Number of subjects: 128
Study 25793773 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 day regimen (2 injections of 7 mg/kg in 3 days)
Number of subjects: 163
Study 25793773 — intervention group
Group type: COMPARATOR
Intervention: 7 day regimen (3 injections of 4 mg/kg per injection in 7 days)
Number of subjects: 163
Study 24011061 — intervention group
Group type: EXPERIMENTAL
Intervention: Group Family Nurse Partnership (gFNP) program
Number of subjects: 0
Study 24011061 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 0
Study 21140160 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-descent vaginal hysterectomy (NDVH)
Number of subjects: 90
Study 21140160 — intervention group
Group type: COMPARATOR
Intervention: Total laparoscopic hysterectomy (TLH)
Number of subjects: 90
Study 21140160 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic assisted vaginal hysterectomy (LAVH)
Number of subjects: 90
Study 20003311 — intervention group
Group type: EXPERIMENTAL
Intervention: Seven-day leadership course
Number of subjects: 0
Study 20003311 — intervention group
Group type: COMPARATOR
Intervention: Multi-source feedback alone (control)
Number of subjects: 0
Study 16455831 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol
Number of subjects: 49
Study 16455831 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study 16455831 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose budesonide
Number of subjects: 49
Study 16455831 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast
Number of subjects: 49
Study 14671247 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment (perindopril and indapamide for eligible participants)
Number of subjects: 6105
Study 11414008 — intervention group
Group type: EXPERIMENTAL
Intervention: Attention focused on subjective contours
Number of subjects: 0
Study 11414008 — intervention group
Group type: EXPERIMENTAL
Intervention: Attention focused on overlapping figures
Number of subjects: 0
Study 9226286 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 28
Study 9226286 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 28
Study 9226286 — intervention group
Group type: COMPARATOR
Intervention: Both Atenolol and Metoprolol
Number of subjects: 28
Study 7679610 — intervention group
Group type: EXPERIMENTAL
Intervention: Bleomycin administered intravenously on a weekly basis
Number of subjects: 1
Study 7679610 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral etoposide therapy
Number of subjects: 1
Study 7679610 — intervention group
Group type: COMPARATOR
Intervention: Radiation treatment regimens (8 Gy in a single fraction and 20 Gy in ten fractions)
Number of subjects: 1
Study 3689634 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole (40 mg day‐1) for 9 days
Number of subjects: 10
Study 3689634 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 28940192 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral language programme (N = 103)
Number of subjects: 208
Study 28940192 — intervention group
Group type: COMPARATOR
Intervention: Active control programme targeting motor skills (N = 105)
Number of subjects: 208
Study 26829343 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic Floor Physical Therapy (PFPT) - 4 sessions
Number of subjects: 54
Study 26829343 — intervention group
Group type: COMPARATOR
Intervention: Control group (no PFPT)
Number of subjects: 54
Study 26829343 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (PFPT and Control)
Number of subjects: 54
Study 25060372 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylaxis with second-generation cephalosporins
Number of subjects: 5158
Study 25060372 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-operative antibiotic duration >48 h
Number of subjects: 5158
Study 25060372 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress hyperglycemia
Number of subjects: 5158
Study 25060372 — intervention group
Group type: EXPERIMENTAL
Intervention: Intubation time of 24 to 48 h
Number of subjects: 5158
Study 25060372 — intervention group
Group type: EXPERIMENTAL
Intervention: Ventilation >48 h
Number of subjects: 5158
Study 25060372 — intervention group
Group type: EXPERIMENTAL
Intervention: Major infections
Number of subjects: 5158
Study 25060372 — intervention group
Group type: EXPERIMENTAL
Intervention: Transfusion by surgery type (excluding left ventricular assist device procedures/transplant)
Number of subjects: 5158
Study 23079491 — intervention group
Group type: COMPARATOR
Intervention: Working Memory Training (WMT)
Number of subjects: 0
Study 19757213 — intervention group
Group type: EXPERIMENTAL
Intervention: Berberine (300 mg orally three times daily)
Number of subjects: 78
Study 19757213 — intervention group
Group type: COMPARATOR
Intervention: Control (no berberine)
Number of subjects: 78
Study 18228568 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 858
Study 16162694 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciclesonide 640 microg bid (CIC 640)
Number of subjects: 60